Boston Scientific to Acquire Nalu Medical - Gilde Healthcare

Menu
Menu
Home

Boston Scientific to Acquire Nalu Medical

Geoff Pardo

General Partner Healthtech
Venture&Growth
Vereinigte Staaten

Karthik Bolisetty

Investment Manager Healthtech
Venture&Growth
Vereinigte Staaten
17. Oktober 2025
Utrecht (the Netherlands) & Boston, MA (United States)

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation.

Nalu Medical markets a miniaturized implantable neurostimulation device to treat patients with chronic neuropathic pain.
Boston Scientific expects to complete the transaction in the first half of 2026, subject to customary closing conditions.

Gilde Healthcare co led the $104m financing round in 2022 and Geoff Pardo serves on the Board of Directors.

Press Release

Mehr neuigkeiten

Gilde Healthcare legt Climate Solutions Fonds auf und erzielt beim ersten Closing €250 Mio.

Mit Commitments internationaler Pensionsfonds, Banken, Fund-of-Funds, Endowments und Family Offices erreicht Gilde Healthcare ein erstes Closing in Höhe von €250 Mio Die Erweiterung um Climate Solutions baut auf Gilde Healthcare‘s Erfolgsbilanz im Bereich des Impact...
18. Februar 2026

Gilde Healthcare Company Big Health Secures Funding to Accelerate Adoption of Digital Mental Health Treatments

New investment fuels expansion as leading health systems adopt evidence-based digital care, driven by new billing codes and strong demand for proven mental health solutions. Big Health, a leading developer of digital treatments for the...
12. Februar 2026

Gilde Healthcare company SpyGlass Pharma announces pricing of initial public offering at NASDAQ

SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per...
6. Februar 2026